Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

Trial Profile

Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telmisartan (Primary)
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use
  • Acronyms TELEX

Most Recent Events

  • 04 Oct 2022 Primary endpoint has not been met (Six-minute walk performance) , according to Results published in the JAMA: the Journal of the American Medical Association
  • 04 Oct 2022 Results published in the JAMA: the Journal of the American Medical Association
  • 29 Aug 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top